Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 15/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32690787 | 0.89 | PARP14 (0.47) | PARP14HDAC1BRD4RXFP1 | |
| SCHEMBL32690766 | 0.89 | PARP14 (0.43) | PARP14HDAC6HDAC1HDAC3HDAC7 | |
| SCHEMBL32690790 | 0.88 | HDAC6 (0.45) | HDAC6HDAC1BRD4HDAC3HDAC7 | |
| SCHEMBL32690829 | 0.84 | RORC (0.43) | HDAC6HDAC1HDAC3HDAC7HDAC10 | |
| SCHEMBL32690666 | 0.84 | RORC (0.43) | PARP14HDAC6HDAC1BRD4HDAC3 | |
| SCHEMBL32690729 | 0.83 | PARP14 (0.42) | PARP14HDAC6HDAC1HDAC3HDAC7 | |
| SCHEMBL32690674 | 0.82 | HDAC1 (0.43) | PARP14HDAC6HDAC1HDAC3HDAC7 | |
| SCHEMBL32690722 | 0.82 | HDAC1 (0.43) | PARP14HDAC6HDAC1HDAC3HDAC7 | |
| SCHEMBL32690827 | 0.82 | HDAC1 (0.43) | PARP14HDAC6HDAC1HDAC3HDAC7 | |
| SCHEMBL32690797 | 0.77 | PARP14 (0.42) | PARP14HDAC6HDAC1HDAC3HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085046-A1 | Dual Function Compounds For NADPH Oxidase Inhibition And Histone Deacetylase Inhibition | TAIWANJ PHARMACEUTICALS CO LTD (TW) | 2026-03-26 | — | — | US | claimed |
| US-20260085046-A1 | Dual Function Compounds For NADPH Oxidase Inhibition And Histone Deacetylase Inhibition | TAIWANJ PHARMACEUTICALS CO LTD (TW) | 2026-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085046-A1 | Dual Function Compounds For NADPH Oxidase Inhibition And Histone Deacetylase Inhibition | NOX1, NOX4, CYBB | PARP14 583/4885HDAC6 10/4885HDAC1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.